Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

354
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
354
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

392
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
392
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

384
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
384
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

379
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
379
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

384
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
384
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

222
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
222

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of a single‑item patient‑reported measure of treatment side‑effect burden in clinical trials of rheumatic and musculoskeletal diseases using stakeholder input and large language model refinement.

Seminars in arthritis and rheumatism·2026
Same author

Measuring disease activity in juvenile systemic sclerosis: a multidisciplinary consensus from the Hamburg 2024 symposium.

Expert review of clinical immunology·2026
Same author

Integrated transcriptomic and epigenomic profiling reveals conserved molecular subtypes across systemic autoimmune diseases.

Annals of the rheumatic diseases·2026
Same author

Integrated single-cell transcriptomic analysis identifies <i>PF4</i> <sup><i>+</i></sup> <i>/PPBP</i> <sup><i>+</i></sup> megakaryocyte-like granulocytes associated with immune dysregulation in autoimmune diseases.

Biochemistry and biophysics reports·2026
Same author

Serum KL-6 and lung ultrasound B-lines: a combined non-invasive model for screening and predicting interstitial lung disease in idiopathic inflammatory myopathy.

RMD open·2026
Same author

Validity and utility of a single-item patient-reported measure of treatment-related bother in rheumatoid arthritis: A cross-sectional OMERACT study.

Seminars in arthritis and rheumatism·2026
Same journal

Comparison of Systemic Corticosteroid Therapy Practices Between Pediatric and Adult Rheumatologists: A Multicenter Survey Study.

Rheumatology and therapy·2026
Same journal

Psychological Aspects of Rheumatic Diseases: Psychorheumatology in Clinical Practice.

Rheumatology and therapy·2026
Same journal

Effectiveness and Safety of Inebilizumab for IgG4-Related Disease in a Real-World Clinical Setting in Japan: Protocol for a Long-Term Prospective Observational Study (4SigHT Study).

Rheumatology and therapy·2026
Same journal

Optical Spectral Transmission Imaging in Patients with Osteoarthritis: A Comparative Study with Joint Ultrasound and Clinical Markers.

Rheumatology and therapy·2026
Same journal

Clinically Amyopathic Dermatomyositis: Epidemiology, Clinical Presentation, Pathophysiology, Treatment, and Prognosis: A Systematic Review.

Rheumatology and therapy·2026
Same journal

Protective Effects of Apolipoprotein A and High-Density Lipoprotein Cholesterol Against Interstitial Lung Disease in Rheumatoid Arthritis: The Mediating Role of Systemic Inflammation.

Rheumatology and therapy·2026
See all related articles

Related Experiment Video

Updated: Dec 26, 2025

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

716

Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized

Roy Fleischmann1, Daniel E Furst2, Erin Connolly-Strong3

  • 1University of Texas Southwestern Medical Center, Metroplex Clinical Research Center, 8144 Walnut Hill Lane, Suite 810, Dallas, TX, 75231, USA. rfleischmann@arthdocs.com.

Rheumatology and Therapy
|March 19, 2020
PubMed
Summary
This summary is machine-generated.

Repository corticotropin injection (RCI) effectively treated active rheumatoid arthritis (RA) in patients already on corticosteroids and DMARDs. Over 60% achieved low disease activity, which was sustained with continued RCI therapy.

Keywords:
Active diseaseClinical trialCorticosteroidsDisease-modifying antirheumatic drugsLow disease activityRepository corticotropin injectionRheumatoid arthritisWithdrawal study

More Related Videos

Knee Arthrocentesis in Adults
04:41

Knee Arthrocentesis in Adults

Published on: February 25, 2022

8.9K
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

754

Related Experiment Videos

Last Updated: Dec 26, 2025

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

716
Knee Arthrocentesis in Adults
04:41

Knee Arthrocentesis in Adults

Published on: February 25, 2022

8.9K
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

754

Area of Science:

  • Rheumatology
  • Immunology
  • Pharmacology

Background:

  • Active rheumatoid arthritis (RA) poses challenges even with standard corticosteroid and disease-modifying antirheumatic drug (DMARD) treatments.
  • Repository corticotropin injection (RCI) is being evaluated for its efficacy and safety in managing RA.
  • This study specifically targets patients with active RA who are inadequately controlled by existing therapies.

Purpose of the Study:

  • To assess the efficacy and safety of repository corticotropin injection (RCI) in patients with active rheumatoid arthritis (RA).
  • To evaluate RCI's effectiveness in subjects with active RA despite concurrent corticosteroid and DMARD therapy.
  • To determine if RCI can help achieve and maintain low disease activity (LDA) in RA patients.

Main Methods:

  • An open-label phase (Part 1) involved 259 subjects receiving RCI (80 U) twice weekly for 12 weeks.
  • Subjects achieving low disease activity (LDA) entered a 12-week double-blind, placebo-controlled phase (Part 2), with 154 subjects randomized.
  • Primary endpoint: proportion achieving LDA (DAS28-ESR < 3.2) at week 12; secondary endpoints included LDA maintenance and CDAI ≤ 10 at weeks 12 and 24.

Main Results:

  • At week 12, 62.9% of subjects achieved LDA (p < 0.0001) and 65.3% achieved CDAI ≤ 10 (p < 0.0001).
  • In Part 2, 61.0% of RCI-treated subjects maintained LDA at week 24, compared to 42.1% of placebo-treated subjects (p=0.019).
  • Maintenance of CDAI ≤ 10 was also significantly higher in the RCI group (85.7%) versus placebo (65.8%) at week 24 (p=0.004).

Conclusions:

  • Repository corticotropin injection (RCI) demonstrated efficacy and a favorable safety profile in active RA patients refractory to standard treatments.
  • RCI significantly increased the proportion of patients achieving LDA by week 12, with sustained benefits observed.
  • The study supports RCI as a viable therapeutic option for managing active RA, offering sustained disease control.